专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090111093A1 Methods and compositions for pre-symptomatic or post-symptomatic diagnosis of alzheimer's disease and other neurodegenerative disorders 审中-公开
标题翻译：阿尔茨海默病和其他神经退行性疾病症状或症状后症状诊断的方法和组合物
公开(公告)号：US20090111093A1
公开(公告)日：2009-04-30
申请号：US10594825
申请日：2005-03-29
申请人： Douglas C. Wallace , Pinar E. Coskun
发明人： Douglas C. Wallace , Pinar E. Coskun
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： Methods, compositions and apparatus (e.g., test kits, test systems, reagents, related computer software, calculators, etc.) for pre-symptomatic or post-symptomatic diagnosis of Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. Also, methods, compositions and apparatus assessing the efficacy of treatments for such disorders. Sample cells, tissue or body fluid are obtained from a human or animal subject and analyzed to determine whether or to what extent certain mitochondrial DNA control region (mtDNA CR). Significantly elevated numbers of these mtDNA CR mutations may indicate that the subject suffers from, or is at increased risk for development of, Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. A significant decrease in the numbers of these mtDNA CR mutations during treatment for the disorder may indicate that the treatment is effective.
摘要翻译：用于阿尔茨海默病或与β-淀粉样蛋白沉积形成相关的其他疾病的症状性或症状后症状的方法，组合物和装置（例如测试试剂盒，测试系统，试剂，相关的计算机软件，计算器等）例如斑块）和/或β-淀粉样蛋白原纤维。此外，方法，组合物和装置评估治疗对这种疾病的功效。样品细胞，组织或体液从人或动物受试者获得并分析以确定某些线粒体DNA控制区（mtDNA CR）是否或在何种程度上。这些mtDNA CR突变的数量显着增加可能表明该受试者患有阿尔茨海默病或与β-淀粉样蛋白沉积物形成有关的其他疾病（例如斑块）和/或β-淀粉样蛋白原纤维。治疗期间这些mtDNA CR突变的数量显着减少可能表明治疗有效。

IPRDB

热门服务

关于我们

友情链接

联系方式